Lynparza

Active substance Olaparib
Holder AstraZeneca NV/SA
Status Running
Indication Lynparza® (olaparib) in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 05/11/2024

 

Last updated on 07/11/2024